CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,420,804 | -62.1% | 248,319 | -44.8% | 0.00% | -50.0% |
| Q2 2023 | $14,313,543 | +0.9% | 450,253 | -22.6% | 0.00% | -33.3% |
| Q1 2023 | $14,189,614 | +48.1% | 581,780 | +91.6% | 0.00% | +50.0% |
| Q4 2022 | $9,578,067 | -25.1% | 303,680 | -32.8% | 0.00% | -33.3% |
| Q3 2022 | $12,780,000 | +130.6% | 452,223 | +115.8% | 0.00% | +200.0% |
| Q2 2022 | $5,541,000 | +29.0% | 209,529 | +70.8% | 0.00% | – |
| Q1 2022 | $4,295,000 | -74.8% | 122,669 | -76.7% | 0.00% | – |
| Q4 2021 | $17,068,000 | +105.3% | 526,526 | +86.8% | 0.00% | -100.0% |
| Q3 2021 | $8,314,000 | +114.8% | 281,854 | +86.6% | 0.00% | – |
| Q2 2021 | $3,870,000 | +49.7% | 151,062 | -19.8% | 0.00% | – |
| Q1 2021 | $2,585,000 | +246.5% | 188,288 | +318.4% | 0.00% | – |
| Q4 2020 | $746,000 | – | 45,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |